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Introduction 
INTRODUCTION 
Systemic corticosteroids are one of the commonly prescribed drugs for 
dermatological conditions. Conventional corticosteroids was associated with many 
side effects like hypertension, hyperglycemia, eye changes like cataract, glaucoma, 
bone changes like osteoporosis, avascular necrosis. Corticosteroids in the form of 
intravenous pulse therapy are used to treat autoimmune disorders like 
pemphigus1,bullous pemphigoid, vitiligo, alopecia areata2.Oral steroid minipulse has 
been tried in conditions like vitiligo3,alopecia areata4,5.Corticosteroids steroids like 
betemethasone4,prednisolone5 and methylprednisolone3 has been used for minipulse 
therapy .Oral methylprednisolone has been used safely in pediatric age group3 also. 
The side effects of steroids are minimal when given in the form of pulse therapy 
compared to daily conventional dose. 
Hyperglycemia is one of the many known side effects of corticosteroid 
therapy, particularly when these drugs are administered in high doses6.The pattern of 
steroid induced hyperglycemia is post-prandial hyperglycemia7. 
Acute hyperglycemia and ongoing high blood glucose levels have been linked 
to increased risk for infection, poor cardiovascular outcome, thrombosis, 
inflammation, endothelial cell dysfunction and enhanced neuronal damage after 
ischaemic brain injury6. 
One of our patient who was on oral methylprednisolone minipulse met with a 
road traffic accident .after hospitalization it was found that his blood sugar was more 
than 450mg/dl .He required emergency measures to bring down the blood sugar 
levels. We initiated this study to know the effects of oral methylprednisolone 
minipulse on blood sugar.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim & Objective 
AIMS AND OBJECTIVES 
1. To determine post-prandial blood sugar before and after giving oral 
methylprednisolone minipulse. 
2. To observe for hyperglycemic symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
STEROIDS 
History 
Addision described fatal outcomes in patients with adrenal destruction in a 
presentation to the South London Medical Society in 1849. These studies were soon 
extended when Brown – Sequard demonstrated that bilateral adrenalectomy was fatal 
in laboratory animals. It later was shown that the adrenal coetex, rather than the 
medulla, was essential for survival in these experiments. 
Studies of the factors that regulated carbohydrate metabolism (termed 
glucocorticoids) culminated with the synthesis of cortisone, the first 
pharmacologically effective glucocorticoid to become readily available. 
Subsequently, Tate and colleagues isolated and characterized a distinct 
corticosteroids, aldosterone, which potently affected fluid and electrolyte balance and 
therefore was termed a mineralocorticoid. The isolation of distinct corticosteriods that 
regulate carbohydrate metabolism or fluid and electrolyte balance led to the concept 
that the adrenal cortex comprises two largely independent units: an outer zone that 
produces mineralcorticoids and an inner region that synthesizes glucocorticoids and 
androgen precursors. 
Studies of adrenocortical steroids also played a key part in delineating the role 
of the anterior pituitary in endocrine function. As early as 1912, Cushing described 
patients with hypercorticism, and later recognized that pituitary basophilism caused 
the adrenal over activity, thus establishing the link between the anterior pituitary and 
adrenal function. These studies led to the purification of ACTH and the determination 
of its chemical structure. ACTH was further shown to be essential for maintaining the 
structural integrity and steroidogenic capacity of the inner cortical zones. Harris 
established the role of the hypothalamus in pituitary control and postulated that a 
soluble factor produced by the hypothalamus activated ACTH release. These 
investigations culminated with the determination of the structure of corticotrophin 
releasing hormone (CRH), a hypothalamic peptide that regulate secretion of ACTH 
from the pituitary. 
Action on the Adrenal Cortex 
Acting via MC2R, ACTH stimulates the adrenal cortex to secrete 
glucocorticoids, mineralocorticoids, and the androgen precursor 
dehydroepiandrosterone (DHEA) that can be converted peripherally into more potent 
androgens. The adrenal cortex histologically and functionally can be separated into 
three zones that produce different steroids products under different regulatory 
influences. The outer Zona glomerulosa secretes the glucocorticoid cortisol, and the 
inner zona reticularis secretes DHEA and its sulfated derivative. 
  
 
 
 
 
Fig: The adrenal cortex contains three anatomically and functionally distinct 
compartments. 
Cells of the outer zone have receptors for angiotensin II and express 
aldosterone synthase (CYP11B2), an enzyme that catalyzes the terminal reactions in 
mineralocorticoid biosynthesis. Although ACTH actuetly stimulates 
mineralocorticoid production by the zona glomerulosa, this zone is regulated 
predominantly by angiotensin II and extracellular K+ and does not undergo atrophy in 
the absence of ongoing stimulation by the pituitary gland. In the setting of persistently 
elevated ACTH, mineralocorticoid levels initially increase and then return to normal. 
In contrast, cells of the zona fasciculata have fewer receptors for angiotensin II 
and express two enzymes, steroid 17 α-hydroxylase (CYP17) and 11β-hydroxylase 
(CYPIIB1), which catalyze the production of glucocorticoids. In the zona reticularis, 
CYP17 carries out a second 17-20 lyase reaction that converts C21 corticosteroids to 
C 19 androgen precursors. 
In the absence on the anterior pituitary, the inner zones of the cortex atrophy, 
and the production of glucocorticoids and adrenal androgens is markedly 
impaired.Persistently elevated levels of ACTH, due either to repeated administration 
of large doses of ACTH or to excessive endogenous production, induce hyperplasia 
and hypertrophy of the inner zones of the adrenal cortex, with overproduction of 
cortisol and adrenal androgens. Adrenal hyperplasia is most marked in congenital 
disorders of steroidogenesis, in which ACTH levels are continuously elevated as a 
secondary response to impaired cotrisol bio synthesis. There is some debate regarding 
the relative roles of ACTH versus other POMC derived peptides in stimulating 
adrenal growth, but the essential role of the anterior pituitary in maintaining the 
integrity of the zone fasciculata is indisputable.  
Hypothalamic – Pituitary – Adrenal Axis 
The rate of glucocorticoid secretion is determined by fluctuations in the 
release of ACTH by the pituitary corticotropes. These corticotropes, in turn, are 
regulated by corticotrophin-releasing hormone (CRH), a peptide hormone released by 
CRH neurons of the endocrine hypothalamus. These three organs collectively are 
referred to as the hypothalamic- pituitary- adrenal (HPA) axis, an integrated system 
that maintains appropriate levels of glucocorticoids. There are three characteristic 
modes of regulation of the HPA axis: diurnal rhythm in basal steroidogenesis, 
negative feedback regulation by adrenal corticosteroids, and marked increase in 
steroidogenesis in response to stress. The diurnal rhythm is entrained by higher 
neuronal centers in response to sleep- wake cycles, such that levels of ACTH peak in 
the early morning hours, causing the circulating glucocorticoid levels to peak at 
approximately 8 A.M. As discussed below, negative feedback regulation occurs at 
multiple levels of the HPA axis and is the major mechanism that maintains circulating 
glucocorticoid levels in the appropriate range. Stress can override the normal negative 
feedback control mechanisms, leading to marked increase in plasma concentrations of 
glucocorticoid. 
 
 
 
 
 
 
 
 
 
Fig: Overview of the hypothalamic-pituitary-adrenal (HPA) axis and the 
immune inflammatory network. 
Negative Feedback of Glucocorticoids 
Glucocorticoids inhibit ACTH secretion via direct and indirect actions on 
CRH neurons to decrease CRH mRNA levels and CRH release and via direct effects 
on corticotropes. The inhibition of CRH release may be mediated by specific 
corticosteroid receptors in the hippocampus. At lower cortisol levels, the 
mineralcorticoid receptor (MR), which has a higher affinity for glucocorticoids and is 
the predominant form found in the hippocampus, is the major receptor species 
occupied. As glucocorticoid concentrations rise and exceed the capacity of the MR, 
the glucocorticoid receptor (GR) also becomes occupied. Both classes of receptor 
apparently control the basal activity of the HPA axis, whereas feedback inhibition by 
glucocorticoids predominantly involves the GR. 
The Stress Response 
Stress overcomes negative feedback regulation of the HPA axis, leading to a 
marked rise in corticosteroid production. Example of stress signals include injury, 
hemorrhage, severe infection, major surgery, hypoglycemia, cold, pain and fear. 
Although the precise mechanisms that underlie this stress response and the essential 
actions played by corticosteroids are not fully defined, it is clear that their increased 
secretion is vital to maintain homeostasis in these stressful settings. As discussed 
below, complex interactions between the HPA axis and the immune system may be a 
fundamental physiological component of this stress response. 
Adrenocortical steroids 
The adrenal cortex synthesizes two classes of steroids, the corticosteroids 
(glucocorticoids and mineralocorticoids) and the androgens. The actions of 
corticosteroids historically were described as glucocorticoid (carbohydrate 
metabolism - regulating) and mineralocorticoid (electrolyte balance - regulating). In 
humans cortisol (hydrocortisone) is the main glucocorticoid and aldosterone is the 
main mineralocorticoid. 
Pharmacology 
Structure 
The basic structure of all corticosteroids consists of three hexane rings and one 
pentane ring(8). The ring structure is known as the cyclopentano 
perhydrophenanthrene nucleus. Cortisone and hydrocortisone both possess a 4, 5 
double bond and a ketone carbonyl group at the 3 position 2,3. Cortisone which is an 
inactive form has a ketone at the 11 position. The active from, hydrocortisone 
(cortisol) is formed through hepatic conversion of the 11- ketone to an 11-hydroxyl 
group. Prednisone is formed by addition of a 1, 2 double bond and through 11- 
hydroxylation the active analog prednisolone is formed. By the addition of a 6 – 
methyl group to prednisolone,. methyl prednisolone is formed. 
Absorption and transport 
Corticosteroids provided exogenously are absorbed in the upper jejunum . 
Food delays, but does not decrease the amount of prednisone absorbed. Peak plasma 
levels are reached 30-100 minutes after drug is taken. 
After absorption 90% or more of cortisol in plasma is reversibly bound to 
protein under normal circumstances .Only the unbound corticosteroid can enter cells 
to mediate corticosteroid effects. Two plasma proteins account for steroid binding 
capacity: corticosteroid binding protein (CBG; also called transcortin) and albumin. 
CBG is the primary endogenous carrier protein8. 
CBG is decreased by hypothyroidism, liver disease, renal disease, and obesity 
all of which result in increased amount of corticosteroid free fraction10. CBG is 
increased by estrogen therapy, pregnancy and hyperthyroidism, all decrease the 
corticosteroid free fraction .All endogenous and synthetic corticosteroids are well 
distributed into fetal tissue with the exception of prednisone8. 
Compound 
Anti 
inflammatory 
potency 
Na+ - 
Retaining 
Potency 
Duration of 
action* 
Equivalent 
dose, MG 
Cortisol 1 1 S 20 
Cortisone 0.8 0.8 S 25 
Fludrocortisone 10 125 I - 
Prednisone 4 0.8 I 5 
Prednisolone 4 0.8 I 5 
6α - 
Methylprednisolone 
5 0.5 I 4 
Triamcinolone 5 0 I 4 
Betamethasone 25 0 L 0.75 
Dexamethasone 25 0 L 0.75 
S - Short (8-12 hour biological half –life) 
I – Intermediate (12-36 hour biological half –life) 
L – Long (36 - 72 hour biological half –life) 
Metabolism and excretion 
The adrenocortical steroids have a double bond in the 4, 5 – position and a 
ketone group at C3. Reduction of 4, 5 double bond occurs at both hepatic and 
extrahepatic sites yielding inactive compounds. Subsequent reduction of the 3- ketone 
substituent to the 3 – hydroxyl derivative forming tetrahydrocortisol, occurs only in 
the liver. These A-ring reduced steroids are conjugated in the liver forming sulfate 
esters and glucuronides which are water soluble and excreted in urine. 
Mechanisms for corticosteroid effects 
Corticosteroids interact with specific receptor proteins in target tissues to 
regulate the expression of corticosteroid responsive genes, thereby changing the levels 
and array of proteins synthesized by the various target tissues. (Fig) As a consequence 
of the time required to modulate gene expression and protein synthesis, most effects 
of corticosteroids are not immediate but become apparent after several hours. 
Although corticosteroids predominantly act to increase expression of target 
genes, there are well documented examples in which corticosteroids decrease 
transcription of target genes. In addition to these genomic effects some immediate 
actions of corticosteroids may be mediated by membrane a bound receptors 
  
 
 
 
 
 
 
Fig: Intracellular mechanism of action of the glucocorticoid receptors 
Glucocorticoid Receptors 
The Glucocorticoid receptor resides predominantly in the cytoplasm in an 
inactive form until it binds glucocorticoids .Steroid binding results in receptor 
activation and translocation to the nucleus. The inactive GR is complexed with other 
proteins, including Heat shock protein 90; HSP 70 and a 56,000 dalton immunophilin, 
one of the group of intracellular proteins that bind the immunosuppressive agents 
cyclosporine and tacrolimus. HSP 90, through interactions with the steroid-binding 
domain may facilitate folding of the GR into an appropriate conformation that permits 
ligand binding. 
The GR are members of the nuclear receptor family of transcription factors 
that transduce the effects of a diverse array of small, hydrophobic ligands, including 
the steroid hormones, thyroid hormones, vitamins D and retinoids. Mutations leading 
to partial loss of glucocorticoid receptor function have been identified in rare patients 
with generalized glucocorticoid resistance . 
Regulation of Gene Expression by corticosteroids 
After ligand binding, the GR dissociates from its associated proteins and 
translocates to the nucleus. In the nucleus it interacts with specific DNA sequences 
within the regulatory regions of affected genes. The short DNA sequences that are 
recognized by the activated GR are called glucocorticoid responsive elements. It 
provides specificity to the induction of gene transcription by glucocorticoids. 
The mechanism by which GR activates transcription are complex and not 
completely understood, but they involve the interaction of the GR with transcriptional 
coactivators and with proteins that make up the basal transcription apparatus. The 
recognition that the metabolic effects of glucocorticoids generally are mediated by 
transcription, while the anti-inflammatory effects are mediated by transrepression, 
suggests that selective GR ligands may maintain the anti-inflammatory actions while 
lessening the metabolic side effect. 
The GR and MR differ in their ability to inhibit AP -1 mediated gene 
activation, suggesting that differential interactions with other transcription factors 
may underlie their distinct effects on cell function. In addition the MR has a restricted 
effects on cell function. MR is expressed mainly in the kidney (distal convoluted 
tubule and collecting duct), colon, salivary glands, sweat glands and hippocampus. 
Receptor-Independent Mechanism for corticosteroid specificity 
The type 2 isozyme of 11β – hydroxysteroid dehydrogenase (11βHSD2) plays 
a key role in corticosteroid specificity, particularly in the kidney, colon and salivary 
glands. This enzyme metabolizes glucocorticoids such as cortisol to receptor-inactive 
11-keto derivatives such as cortisone. Because its predominant form in physiological 
settings is the hemiacetal derivative, which is resistant to 11 βHSD action, aldosterone 
escapes this reactivation and maintains mineralocorticoid activity. In the absence of 
11 βHSD2, as occurs in an inherited disease called the syndrome of apparent 
mineralocorticoid excess, the MR is swamped by cortisol, leading to severe 
hypokalemia and mineralocorticoid – related hypertension. A state of 
mineralocorticoid excess also can be induced by inhibiting 11 βHSD with glycyrrhizic 
acid, a component of licorice implicated in licorice – induced hypertension. 
Physiological Functions 
The effect of corticosteroids include alterations in carbohydrate, protein, and 
lipid metabolism; maintenance of fluid and electrolyte balance; and preservation of 
normal function of cardiovascular system, the immune system, the kidney, skeletal 
muscle, the endocrine system, and the nervous system. In the absence of adrenal 
cortex, survival is made possible only by maintaining an optimal environment, 
including adequate and regular feedings, ingestion of relatively large quantity of 
sodium chloride, and maintenance of an appropriate environmental temperature, 
stresses such as infection and trauma in this sitting can be life threatening. The anti-
inflammatory and immunosuppressive actions of corticosteroids – one of the major 
"pharmacological" uses of this class of drugs – also provide a protective mechanism 
in the physiological setting. 
Corticosteroids are grouped according to their relative potencies in Na+ 
retention, effects on carbohydrate metabolism (ie. Hepatic deposition of glycogen and 
gluconeogenesis and anti-inflammatory effects). The corticosteroids traditionally are 
divided into mineralocorticoids and glucocorticoids.  
Carbohydrate and protein metabolism 
Corticosteroids stimulate the liver to form glucose from amino acids and 
glycerol and to store glucose as liver glycogen. In the periphery glucocorticoids 
diminish glucose utilization, increase protein breakdown and the synthesis of 
glutamine, and activate lipolysis, thereby providing amino acids and glycerol for 
gluconeogenesis. The net result is to increase blood glucose levels. Because of their 
effects on glucose metabolism glucocorticoids can worsen glycemic control in 
patients with overt diabetes and can precipitate the onset of hyperglycemia in patients 
who are otherwise predisposed. 
Lipid metabolism 
Two effects of corticosteroids on lipid metabolism. First is the dramatic 
redistribution of body fat that occurs in settings of endogenous or pharmacologically 
induced hypercorticism, such as Cushing's syndrome. The other is the permissive 
facilitation of the lipolytic effect of other agents such as growth hormone and β 
adrenergic receptor agonists, resulting in an increase in free fatty acids after 
glucocorticoid administration. With respect to fat distribution, there is increased fat in 
the back of the neck ("buffalo hump") face ("moon facies") and supraclavicular area, 
coupled with a loss of fat in the extremities. 
Electrolyte and water balance 
Aldosterone is by far the most potent endogenous corticosteroid with respect 
to fluid and electrolyte balance. Thus electrolyte balance is relatively normal in 
patients with adrenal insufficiency due to pituitary disease. Mineralocorticoids act on 
the distal tubules and collecting ducts of the kidney to enhance reabsorption of Na+ 
from the tubular fluid; they also increase the urinary excretion of K+ and H+. The 
primary features of hyperaldosteronism are Na+ balance with consequent expansion 
of extracellular fluid volume, normal or slight increase in plasma Na+ 
concentration,hypokalemia and alkalosis.Mineralocorticoid deficiency leads to Na+ 
wasting and contraction of the extracellular fluid volume, hyponatremia, 
hyperkalemia and acidosis. Glucocorticoids play a permissive role in the renal 
excretion of free water. 
Glucocorticoids also exert multiple effects on Ca2+ metabolism. Steroids 
interfere with Ca2+ uptake in the gut and increase Ca2+ excretion by the kidney. These 
effects collectively lead to decreased total Ca2+ stores. 
Cardiovasular system 
The effects of corticosteroids on the cardiovascular system result from 
mineralocorticoid – induced changes in renal Na+ excretion, as is evident in primary 
aldosteronism. The resultant hypertension can lead to a diverse group of adverse 
effects on the cardiovascular system, including increased atherosclerosis, cerebral 
hemorrhage, stroke and hypertensive cardiomyopathy. 
The second major action of corticosteroids on the cardiovascular system is to 
enhance vascular reactivity to other vasoactive substances. Hypoadrenalism is 
associated with reduced response to vasoconstrictors such as nor- epinephrine and 
antiotensin II, perhaps due to decreased expression of adrenergic receptors in the 
vascular wall. 
Skeletal muscle 
Corticosteroids are required for the normal function of skeletal muscle, and 
diminished work capacity is a prominent sign of adrenocortical insufficiency. In 
patients with addison's disease, weakness and fatigue are frequent symptoms that may 
reflect on inadequacy of the circulatory system. 
In primary aldosteronism, muscle weakness results primarily from 
hypokalemia rather than from direct effects of mineralocorticoids on skeletal muscle. 
In contrast glucocorticoid excess over prolonged periods either secondary to 
glucocorticoid therapy or endogenous hypercortism, causes skeletal muscle wasting. 
This effect termed steroid myopathy, accounts for weakness and fatigue in patients 
with glucocorticoid excess. 
Formed elements of blood 
Glucocorticoids exert minor effects on hemoglobin and erythrocyte content of 
blood as evidenced by the frequent occurance of polycythemia in cushings syndrome 
and of normochromic normocytic anemia in adrenal insufficiency. More profound 
effects are seen in the setting of autoimmune hemolytic anemia, in which the 
immunosuppressive effects of glucocorticoids can diminish the self – destruction of 
erythrocytes. 
Addisons disease is associated with an increased mass of lymphoid tissue and 
lymphocytosis. Cushing's syndrome is characterized by lymphocytopenia and 
decreased mass of lymphoid tissue. 
Central nervous system 
Corticosteroids exert a number of indirect effects on the CNS, through 
maintenance of blood pressure, plasma glucose concentrations and electrolyte 
concentrations .Increasingly, direct effects of corticosteroids on the CNS have been 
recognized, including effects on mood, behavior and brain excitability. 
Anti-inflammatory and Immunosuppressive actions 
Glucocorticoids can prevent or suppress inflammation in response to multiple 
inciting events, including radiant, mechanical, chemical, infectious and 
immunological stimuli. 
Clinical Uses: 
Pemphigus vulgaris: 
Systemic corticosteroids remain the mainstay of treatment of pemphigus. The 
emphasis here is high dose corticosteroid therapy with use of adjunctive steroid – 
sparing "immunosuppressive therapy. Adjunctive therapy is generally used with a 
choice of Azathioprine, cyclophosphamide, cyclosporine, methotrexate, gold or 
plaspmapheresis. (11, 12, 13) Pulse methylprednisolone may be indicated to attain rapid 
disease control in more severe cases of pemphigus vulgaris14. Pulse dexamethasone 
and cyclophosphamide have been documented as an effective option for moderate to 
severe pemphigus vulgaris15. Early reports on oral corticosteroid therapy for 
pemphigus vulgaris describe doses of 120-140 mg daily of prednisone15, 16. For mild 
to moderate disease the starting dose of prednisolone is 60- 80 mg/day, whereas for 
severe disease treatment is started with 80-120 mg/day17. 
Bullous pemphigoid 
In Bullous pemphigold patients, moderate doses of corticosteroid upto 1mg/kg 
daily are used 12. The suggested initial doses are 20mg or 0.3mg/kg body weight daily 
in localized or mild disease, 40mg or 0.6mg/kg per day in moderately severe disease 
and 50-70mg or 0.75 mg/kg daily in severe disease. About half of the patients require 
concomitant immunosuppressive therapy with drugs such as azathioprine or 
methotrexate19, 20. Deaths still occasionally occur in older patients with more 
extensive involvement; more conservative management utilizing alternatives to 
corticosteroid may help in decreasing the risk of sepsis. 
Cicatricial pemphigoid 
Cicatricial pemphigoid is less responsive to corticosteroid that in bullous 
pemphigoid 18, 22. But still it remains the mainstay initial drugs for moderate-to-severe 
cicatricial pemphigoid 28. In general 1 – 15mg/kg daily of prednisolone is required for 
initial control of moderate – to severe cases.Once the disease is controlled, 
prednisolone should be slowly tapered while continuing with immunosuppressive. 
Dapsone (50 – 200mg/d) is another initial treatment option and if satisfactory results 
are not achieved in 3 months treatment with prednisolone and cyclophosphamide 
should be started24. 
 
Vitligo 
The most frequently used modalities in the treatment of vltiligo are PUVA and 
topical corticosteroids25. In actively spreading vitiligo, PUVA therapy in not an ideal 
treatment. There have been a few reports on the use of systemic steroids in vitiligo 
therapy. Indian dermatologist, Desai and others have long believed that systemic 
prednisolone is a helpful adjunct to photoyherapy.Therapy with betamethasone was 
reported by Pasricha and Khaitan to minimize its side effects27. Another oral mini – 
pulse therapy was studied by Kanwar et al in 37 patients with rapidly spreading 
vitiligo they received dexamethasone minipulse28. 
Alopecia areata 
Despite protestations that systemic steroids have no place in the therapeutic 
plan for alopecia areata, they continue to be used by "Pragmatists." Most authorities 
agree that systemic steroid therapy has a place in arresting the spread of rapidly 
progressing alopecia areata threatening to become total29. Systemic steroids have been 
used in various regimens and dosages in the treatment of extensive alopecia areata 
with variable responses. The high doses of intravenous methylprednisolone for 3 days 
per month have shown good results in patients with multifocal alopecia areata and 
alopecia totalis. In another study by Doulat Rai Bajaj and et.al showed that 
prednisolone oral minipulase therapy is a convenient and effective therapy for the 
treatment of extensive alopecia areata30. 
Steven Johnson Syndrome and Toxic epidermal Necrolysis 
A number of studies support routine Corticosteroid therapy (31, 32) .But still 
there is controversy regarding the use of systemic corticosteroid for the spectrum of 
Steven Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Experience of 
routine systemic corticosteroid use suggest that for SJS and TEN patients, systemic 
corticosteroid treatment early in the disease process (before significant sloughing of 
skin), followed by rapid tapering of corticosteroid may be beneficial and even life 
saving33. Intravenous methylprednisolone in divided doses upto 2 – 2.5 mg/kg daily is 
indicated initially, with relatively rapid tapering when new blister formation ceases. 
Erythema multiforme minor 
A Common indication for moderate corticosteroid doses is recurrent oral 
erythema multiforme (EM) minor. Painful oral erosions respond promptly to 
prednisolone of doses upto 1mg/kg daily, rapidly tapered over 2 – 3 weeks. 
Lupus erythematosus spectrum 
Corticosteroid therapy is generally indicated for systemic disease 
manifestations of lupus erythematosus spectrum. Primary cutaneous indications are 
LE patients with vasculitis and bullous lupus erythematosus, widespread disfiguring 
discoid lupus erythematosus34. Numerous alternatives like anti malarial agents, 
dapsone, retinoids, thalidomide and oral gold are available. And moreover most 
cutaneous LE cases can be managed with sunscreens, topical or intralesional CS and 
antimalarial therapy. Doses of 20 mg every day upto 60mg daily of prednisolone may 
be required. 
Dermatomyositis 
Corticosteroids are the first line agents36. Corticosteroids often as 
monotherapy is indicated in Dermatomyositis. Dermatomyositis is a condition in 
which very slow tapering of syetemic oral corticosteroids over atleast 3-6 months is 
needed. About 90% of patients respond to a prednisolone of dose 1-1.5 mg/kg daily. 
The dose is adjusted on the basis of muscle strength and muscle enzyme levels. 
Vasculitis 
Vasculitis is the cutaneous manifestations of a variety of conditions. The most 
common presentations are palpable purpura from leukocytoclastic vasculitis and 
persistant urticaria lesions associated with urticarial vasulitis. Gastrointestinal, renal 
and joint involvement may indicate systemic corticosteroid therapy. (37, 38) Doses of 
upto 1 mg/kg/d of prednisolone is used successfully for patients with chronic 
cutaneous leukocytoclastic vasculitis with ulcers, infarction or persistent painful 
lesions. And rapid tapering to alternate –day dosing is suggested, prednisolone 20 mg 
(or less) on alternate days is often used. Colchine is an effective alternative to 
corticosteroid therapy in most cases of chronic cutaneous leukocytoclastic vasculitis. 
Pyoderma Gangrenosum 
Systemic corticosteroids are considered as the drug of choice for the treatment 
of pyoderma gangrenosum and are particularly effective in treating the acute, rapidly 
progressive form of the disease. Initial doses of prednisolone in the range of 40 – 
80mg/day of higher are usually required. In some cases steroid pulse therapy may 
produce rapid improvement of the disease that was unresponsive or oral 
corticosteroids; methylprednisolone or dexamethasone pulse therapy has produced 
good results39. Intralesional corticosteroid may be a useful adjunct to the above two 
systemic therapies. 
Lichen Planus 
Systemic steroids are helpful in treating generalized eruptive lichen planus, 
erosive (ulcerative) oral and genital lichen planus, progressive lichen planus and the 
active stage of scalp lichen planus causing alopecia. Prednisolone given at 40 – 60 mg 
daily and tapered overy 4-6 weeks consistently eradicates or reduces the intensity of 
generalized lichen planus. Ideally the regimen should reach a physiologic dose range 
by 3 – 4 weeks. This corticosteroid use is potentially important for darkly pigmented 
races in whom pigment incontinence is most notable. Alternatives such as high 
potency topical corticosteroid gels, intralesional corticosteroid therapy, systemic 
retinoids and cyclosporine all should be considered for patients with oral lichen 
planus. 
Acute dermatitis 
Severe acute contact dermatitis due to poison ivy/poison oak is a classic 
situation in which 2 to 3 week burst of systemic corticosteroid therapy is usually 
successful at minimal risk to the patient. Doses upto 1 mg/kg/day tapered over 2 – 3 
weeks yields adequate improvement with minimal risk of rebound flare after cessation 
of therapy. Doses of prednisolone less than 1mg/kg/day is commonly used for acute 
flares of chronic dermatitis. Exfoliative dermatitis commonly requires systemic 
steroids. Excluding psoriasis exfoliative erythroderma refractory to aggressive topical 
medication or to phototherapy may respond to prednisolone upto 1mg/kg/day. This 
dose is tapered rapidly to low dose alternate day therapy. 
Sarcoidosis 
Ulcerative sarcoidosis or aggressive facial involvement like in lupus pernio 
may indicate systemic corticosteroid therapy. Alterations include antimalarial agents, 
low dose methotrexate and intralesional corticosteroids. 
Androgen excess syndromes 
For recalcitrant acne vulgaris and hirsutism due to elevated adrenal androgens, 
corticosteroid therapy is often indicated. Night time suppressive therapy with low 
dose dexamethasone 0.125 – 0.375mg.45 This timing is important to suppress the early 
morning peak of ACTH, which stimulates adrenal androgen production. 
Post – Herpetic Neuralgia 
A study by Eaglstein suggested that moderate –dose corticosteroid could 
minimize the risk of post herpetic neuralgia. It is reasonable to treat patients with 
facial involvement, patients with severe acute pain during the cutaneous eruption and 
patients over 55-60 years of age with combined antiviral and corticosteroid therapy. It 
is suggested recently that the systemic corticosteroid have a greater role in treating 
acute pain of herpes zoster than for preventing post – herpetic neuralgia.  
Contraindication 
Absolute 
Systemic fungal infections 
Herpes simples keratitis 
Hypersensitivity (with ACTH, IV preparations) 
Relative 
Cardiovascular 
Hypertension 
Congestive heart failure 
Central nervous system 
Prior psychosis 
Severe depression 
Infections 
Active TB 
Positive tuberculin test 
Metabolic 
Diabetes mellitus 
Musculoskeletal 
Osteoporosis 
Ocular 
Cataracts 
Glaucoma 
Pregnancy 
Adverse effects of steroids 
HPA axis 
Steroid withdrawl syndrome 
Addisonian crisis. 
 
Glucocorticoid effects 
Hyperglycemia 
Increased appetite (and weight) 
Mineralocorticoid effects (due to sodium retention, potassium loss) 
Hypertension 
Congestive heart failure 
Excessive weight gain 
Hypolcalcemia 
Lipid effects (↑ lipolysis and altered deposition) 
Hypertriglyceridemia 
Cushingoid changes 
Menstrual irregularity 
Bone and related metabolic effects 
Osteoporosis 
Osteonecrosis 
Hypocalcemia 
 
Gastrointestinal 
Peptic ulcer disease 
Bowel perforation 
Fatty liver changes 
Esophageal reflux 
Nausea, vomiting 
Ocular effects 
Cataracts 
Glaucoma 
Infections 
Refraction Changes 
Psychatric 
Psychosis 
Agitation or personality change 
Depression 
Prednisolone phobia or dependency 
 
Neurologic 
Pseudotumor cerebri 
Epidural lipomatosis 
Peripheral neuropathy 
Infectious 
Tuberculosis reactivation  
Opportunistic – Deep fungi, others 
Prolonged herpes virus infections. 
Muscular 
Myopathy 
Pediatric 
Growth impairment 
Pulse IV therapy 
Electrolyte shifts 
Cardiac dysrrythmias 
Seizures 
 
Potentially fatal complications 
Adrenal crisis (Addisonian crisis) 
Such patients exhibit characteristic symptoms of adrenal insufficiency, 
hypotension and markedly decreased cortisol levels. In the current era this 
complication is extraordinarily rare. 
Bowel perforation 
Tremendous caution should be given with the use of systemic corticosteroids 
after recent bowel anastomosis and for patients with active dliverticulitis. 
Peptic ulcer perforation 
This is more likely with adjunctive non-steroidal anti – inflammatory drugs 
and in patients with a prior peptic ulcer disease. 
Pancreatitis 
This complication largely occurs with triglycerides>800 mg/dl severe 
hyperglycemia (Diabetic ketoacidosis or hyperosmolar non-ketotic coma). 
Most severe hyperglycemia occurs with pre existing diabetes mellitus, the 
widespread availability to home glucose monitoring should make this a rare 
complication. 
 
 
Opportunistic infections 
These infections are uncommon with corticosteroids used for dematologic 
indications and it primarily occurs with multidrug immunosuppression regimens for 
systemic autoimmune disorders and for organ transplantation. 
Immunosuppresion carcinogenesis 
Opportunistic malignancies denote kaposi's sarcoma, non-hodgkins 
lymphoma, squamous cell carcinoma that are common in organ transplantation 
patients. This is very uncommon with systemic corticosteroids for purely 
dermatologic indications. 
Other Adverse effects 
Osteonecrosis (Avascular necrosis, aseptic necrosis): 
The majority of osteonecrosis cases are with pharmacologic doses of 
prednisone (or comparable doses of other systemic corticosteroids) for at least 2 – 3 
months for life threatening conditions. 
Osteoporosis 
Preventive measures to retard the expected corticosteroid induced bone 
calcium depletion for any patient receiving pharmacologic doses of corticosteroid for 
atleast one month are imperative. The options includes calcium (1000 – 1500 mg 
daily), vitamin D (800 U daily), bisphosphonates, estrogens, and calcitonin. 
 
Growth impairment in Children 
This is rare with dermatological indications. 
Cutaneous adverse effects from systemic corticosteroids 
Wound healing and related changes 
− Non healing wounds, ulcers, striae, atrophy, telangiectasis, 
Pilosebaceous 
Steroid ance, steroid rosacea, 
Vascular 
Purpura, including actinic purpura 
Cutaneous infections 
Staphylococal, herpes virus infections 
Hair effects 
Telogen effluvium, hirsutism 
Injectable corticosteroid 
Fat atrophy, crystallization of injectable material 
Other skin effects 
Pustular psoriasis is rare, rebound of poison ivy /oak, acanthosis nigricans 
STEROID INDUCED HYPERGLYCEMIA 
Hyperglycemia is one of the many known side effects of corticosteroid 
therapy, particularly when these drugs are administered in high doses 41,42 
Corticosteroids stimulate the liver to form glucose from amino acids and to store 
glucose as liver glycogen. In the periphery glucocorticoids diminish glucose 
utilization, increase protein breakdown and the synthesis of glutamine, and activate 
lipolysis, thereby providing amino acids and glycerol for gluconeogenesis. The net 
result is to increase blood glucose levels. Because of their effects on glucose 
metabolism, glucocorticoids can worse glycemic control in patients with overt 
diabetes and can precipitate the onset of hyperglycemia, in patients who are otherwise 
predisposed. 
The mechanism by which glucorticoids inhibit glucose utilization in peripheral 
tissues are not fully understood. Glucocorticoids decrease glucose uptake in adipose 
tissue, skin, fibroblasts, thymocytes and polymorphonuclear leukocytes, these effects 
are postulated to result from translocation of the glucose uptake in adipose tissue, 
effects are postulated to result from translocation of the glucose transporters from the 
plasma membrane to an intracellular location. These peripheral effects are associated 
with a number of catabolic actions, including atrophy of lymphoid tissue, decreased 
muscle mass, negative nitrogen balance and thinning of the skin. 
Similarly the mechanisms by which the glucocorticoids promote 
gluconeogenesis are not fully defined, Amino acids mobilized from a number of 
tissues in response to glucocorticoids reach the liver and provide substrate for the 
production of glucose and glycogen, In the liver glucocorticoids induce the 
transcription of a number of enzymes involved in gluconeogenesis and amino acid 
metabolism including phosphoenol pyruvate corboxykinase (PEPCK), glucose 6- 
phosphatase and the bi-functional enzyme fructose – 2, 6 – bisphosphatase. Analyses 
of the molecular basis for regulation of PEPCK gene expression have identified 
complex regulatory influences involving an interplay among glucocorticoids, insulin, 
glucagon and catecholamines.The effect of these harmones and amines on PEPCK 
gene expression mirror the complex regulation of gluconeogenesis in the intact 
organism. 
St. Louis, July 17, 2003 found that a protein called peroxisome proliferator –
activated receptor alpha (PPAR - alpha) is critical in this process and liver plays a 
role. PPAR – alpha is found in the liver, kidney, muscles, blood vessels and other 
organs, since it is activated by fatty acids and since glucocorticoids alter fatty acid 
processing, Bernal –Mizra-Chi and his colleagues hypothesized that the two may act 
together to produce the disease –causing side effects48. They therefore compared mice 
lacking both LDLR and PPAR- alpha with mice lacking only LDLR (receptor for low 
density lipoprotein also known as "bad cholesterol"). 
They found that when given the glucocorticoid dexamethasone, mice lacking 
only LDLR had increased levels of insulin, fasting glucose and leptin, all signs of 
diabetes. Mice lacking both LDLR and PPAR – alpha shoved no sings of diabetes. 
In a recent position statement, the American Diabetes association identified 
corticosteroids as agents that contribute to the occurrence of hyperglycemia44.  
Hyperglycemia was defined as a blood glucose level ≥200 mg/dl from either a 
bedside or a laboratory glucose measurement. 
An excess of steroids impairs the suppression of glucose production and 
stimulation of glucose utilization, which might cause diabetes mellitus or aggravate 
preexistent diabetes. According to these mechanisms abnormal glucose metabolism 
induced by steroids may reflect both fasting and post-prandial hyperglycemia. The 
diabetes epidemiology; collaborative analysis of diagnostic criteria in asia study in 
Japan demonstrated that more than 70% if diabetes mellitus cases were diagnosed 
based on post-prandial hyperglycemia. In a study done by Greenstone and Shaw45 
measuring blood glucose level normalized throughout the next day. Hyperglycemia 
induced by glucocorticoids is primarily an exaggeration of post prandial 
hyperglycemia. Most patients will not have significantly different fasting blood 
glucose levels when they are receiving corticosteroids. Glucocorticoids increase 
hepatic glucose production and can inhibit insulin – stimulated glucose uptake in 
peripheral tissues.46 
Also in a study conducted among the patients with primary renal diseases all 
of the 17 patients were diagnosed as having diabetes mellitus by postprandial 
hyperglycemia with normal fasting blood glucose levels.47 
In another study conducted in 102 patients with rheumatoid arthritis treated 
with methyl prednisolone 8.8% of patients developed diabetes mellitus and six 
patients with existing diabetes mellitus in whom glycaemic control worsened between 
three to six months.48 
In yet another study with high dosage treatment of methylprednisolone therapy 
in severe acute respiratory syndrome of one hundred of thirty three cases. 36.3% were 
diagnosed as corticosteroid induced diabetes49. These patients were treated with high 
doses of methylprednisolone had increased blood sugar level when compared with 
patients treated with corticosteroids of low doses. If the patients were treated with an 
average dose less than 90 mg/day and treatment duration shorter than 15 days the 
diabetes incidence was 10.5%. 
In a literature review, they showed that the total glucocorticoid dose and 
duration of therapy are strong predictors of diabetes induction other risk factors 
include age and body mass index50. Failure to treat glucocorticoid induced 
hyperglycemia is related to the presumed short duration of administration of 
glucocorticoid treatment and the emphasis of fasting plasma glucose only. 
Fluctuations in plasma glucose concentrations, however has been associated 
with increased cardiovascular mortality51. A mechanism for this relationship is 
suggested by studies showing that even short-term or postprandial hyperglycemia is 
associated with acute inflammation and endothelial dysfunction in patients without 
diabetes and in those with type 2 diabetes mellitus.52 Moreover reduced fluctuation in 
glucose levels with administration of insulin decreases these defects.53 
Virtually all currently available agents used in the treatment of type 2 diabetes 
mellitus have been suggested as treatment options for glucocorticoid induced 
hyperglycemia.54 These include sulphonylureas, metformin, thiazolidinediones 
(TZDS) and insulin .Each agent has inherent limitations in patients who require 
Glucocorticoids.55 Long acting sulphonylureas were first used in the long term 
treatment of renal transplant patients, with response rates of 25%. The agents have 
been used in non transplant patients as well. The advantages of these agents are their 
prompt insulin secretory effect and their low cost. Prolonged duration of action with 
most of the agents may increase the risk of hypoglycemia when short term and 
tapering doses of glucocorticoids are prescribed. Shorter acting agents such as 
repaglinide or nateglinide might be more suitable metformin would seem to be a 
reasonable agent because of its effect on insulin sensitivity. In patients requiring long 
term glucocorticoid use in whom renal and liver function is acceptable, metformin 
could be a reasonable choice. Uses of TZDS (for example rosiglitazone and 
pioglitazone) have also been suggested. These agents have been used for long-term 
treatment of transplant induced diabetes mellitus with some success in combination 
with other agents (for example sulphonylureas or insulin) 
Insulin can be used safely and effectively in patient with glucocorticoid 
induced hyperglycemia. Two general approaches have been advocated. The first 
focuses on prandial insulin therapy. The basis for this strategy appears to be the 
observation that, whereas fasting glucose concentrations are typically normal when 
glucocorticoids are administered once daily, glucose levels increase after breakfast 
and particularly after lunch, with a gradual decline toward normal overnight. The rise 
in glucose concentrations throughout the day has then been interpreted as evidence for 
a specific defect in postprandial insulin secretion which should be addressed by 
prandial insulin. 
An alternative strategy is suggested based on the known effect of weight and 
glucocorticoid dose on insulin sensitivity. It is well recognized that as body weight 
(and body fat) increases, insulin resistance also increases. NPH insulin is chosen for 
glucocorticoid induced hyperglycemia because of the time course of action shown in 
available pharmacodynamic data. Just as prednisolone and prednisone have a peak 
action at 4 to 8 hours and a duration of 12 to 16 hours, NPH insulin has a similar 
action profile. A suggested weight based algorithm for insulin based on the known 
dose response effects of glucocorticoid on insulin sensitivity is suggested. The insulin 
doses are averages and may necessitate individual adjustment. 
The advantages of this strategy are many. First it is simple. A single 
administration of insulin is required for most patients and the titration schedule can be 
easily explained. Second it is proactive. Third it reinforces the critical role of patients 
in their own glucose management at a time when dramatic glucocorticoid induced 
increases in glucose values might otherwise lead to frustration. 
Several studies revealed that post prandial hyperglycemia including impaired 
glucose tolerance is a risk factor for mortality and is closely associated with 
cardiovascular disease. In addition authors of another study found that acute 
hyperglycemia (>270 mg/dl) induced significant increases in platelet aggregation and 
blood viscosity, which are regarded as important cardiovascular risk factors. And 
Glucocorticoid induced diabetic ketoacidosis has been reported.56. 
Pulse therapy means the administration of large (Supra – pharmacologic) 
doses of drugs in an intermittent manner to enhance the therapeutic effect and reduce 
the side effects. 
The first reported use of pulse administration of corticosteriods is attributed to 
Kountz and Cohn who used it successfully prevent renal graft rejection. Subsequently 
pulse doses of corticosteroids were used for several other disease such as lupus 
nephritis, rheumatoid arthritis and pyoderma gangrenosum,. But usually to deal with 
emergency situations only and not as a preferred method of treatment. Methyl 
prednisolone was the commonest drug used, in a dose of 1g per dose for a variable 
number of days. For pemphigus the pulse therapy was first used by Pasricha in 1982,  
for systemic sclerosis in 1989, for pyoderma gangrenosum in 1990 and other 
diseases in subsequent years. 
The pulse therapy region designed by Pasricha et al is called DCP regimen or 
the Dexamethosone cyclophosphamide pulse (DCP) therapy regimen. In its present 
form, it consists of giving 100 mg dexamethasone dissolved 1n 500 ml of 5% glucose 
as a slow intravenous drip over 2 hours repeated on 3 consequent days. On the second 
day the patient is also given 500 mg cyclophosphamide in the same drip. This 
constitutes one DCP such DCps are repeated at exactly 28 day intervals counted from 
the day first of the pulse. In between the pulse patient receives only 50 mg cyclo 
phosphamide orally per day. The DCP regimen is administered in four phases. During 
the first few months (phase I) the patient may continue to develop recurrences of 
clinical lesions in between the DCPs and can therefore be given additional treatment 
(conventional daily doses of oral corticosteroids or additional dexamethasone pulses) 
to achieve quicker clinical recovery and these are as a rule withdrawn stepwise during 
the subsequent DCPs. After the skin and the mucous membrane lesions have subsided 
completely and the additional medication has been with drawn, the patient is 
considered to have entered phase II. During this phase, the patient remains completely 
alright clinically but receives 9 more DCPs at exactly 28 days cycles along with 30 
mg cyclophosphamide orally per day. During the next phase (phase III). The DCPs 
are stopped and the patient receives only 20mg cyclophosphamide orally per day for 
the next 9 months. After this the treatment for pemphigus is withdrawn completely 
and the patient is followed up for the next 10 years to took for a relapse in any (phase 
IV). 
Contraindications 
There are almost no contraindications. DCP therapy can be given to patients of 
all ages but the doses have to be reduced to half for children below the age of 12 
years. It can also be given to patients having diabetes mellitus, hypertension, 
hyperacidity, osteoporosis, tuberculosis etc. but each patient must receive additional 
appropriate treatment for the concomitant disease whenever necessary. Diabetic 
patients need to be given 10 units of soluble insulin for every 500 ml bottle of 5 % 
glucose dissolved in the same drip in addition to the routine treatment for diabetes. If 
the patient has severe infected lesions or those is a serious infection elsewhere the 
start of the pulse therapy can be delayed for a week or two till the infection has been 
brought under control.  
The only contraindication for pulse therapy is pregnancy or if the patient is a 
lactating mother and feeding her infant. Patients who are unmarried or those who have 
not yet completed their family and want to have more children have to be given only 
Dexamethasone pulses (DPs). 
Side effects 
The major adverse effects seen. Particularly in the first two phases were 
increased susceptibility to infections for example, secondary bacterial infection of the 
lesions. Oral candidiasis, widespread tinea and the reactivation of dormant 
tuberculosis. The other major side effects were amenorrhea in women, azoospermia in 
men and hair loss. The main advantages of DCP were the quick healing of lesions and 
absence of side effects of corticosteroids (eg: weight gain, diabetes and osteoporosis). 
The commonest immediate side effects of DCP is flushing, followed by the 
more delayed ones like generalized weakness and inadequate sleep syndrome. 
Irreversible amenorrhoea has been noted. Other side effects included a feeling of 
weakness and tiredness due to corticosteroids withdrawl for 2-3 days after the pulse, 
bad taste in the mouth and loose motions coinciding with the pulses. Recurrent 
hiccups after the pulse, cataract, bone pain with similar intention as DCP regimen oral 
minipulse with steroids like Betamethasone, prednisolone and methyl prednisolone 
has been tried in various condition. Its chief aim is to provide maximum efficacy and 
to minimize the side effects of steroids. 
In a study conducted on alopecia patients where the patients treated with 
Betamethasone oral minipulse therapy, they concluded that the oral minipulse therapy 
is a safe and effective treatment modality for extensive alopecia areata4. 
Similarly prednisolone oral mini [pulse therapy has been tried in treatment of 
alopecia areata with success. They concluded that the therapy is a convenient and 
effective therapy for the treatment of extensive alopecia areata of recent onset 5. 
In a study on a vitiligo patients, they treated the patients with low dose 
predinisolone and they concluded that low dose predinisolone is an effective method 
in preventing progression and inducing regimentation of rapid spreading vitiligo 
without serious side effects. 
In another study of childhood vitiligo involving four hundred children treated 
with oral methyl predinisolone on two consecutive days every week in a minipulse 
form for a period of six months with more than 90 % patients went into complete 
remission 6. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methodology  
MATERIALS AND METHODS 
A. Inclusion Criteria 
Patients with alopecia areata, vitiligo, lichen planus were included 
B. Exclusion Criteria 
Patients with diabetes mellitus, associated infections, pregnant women were 
excluded from the study. 
Total of 22 patients were studied. The study was conducted over a period of 
12 months at the Department of Dermatology, Venereology and Leprology, PSG 
Hospitals, Coimbatore, Tamil Nadu. 
Patients were hospitalized for 2 days. On the first day, baseline fasting blood 
sugar was done and 2 hours later post prandial blood sugar was done. 
Estimation of Blood sugar 
The estimation of blood sugar was done by calorimetric method. The values 
were calculated in mg/dl. The normal fasting blood sugar and post prandial blood 
sugar levels were 70 – 110 mg/dl and <140 mg/dl, respectively. 
On day 2 methylpredinisolone 1.7 mg/kg was administered to the patients as a 
single morning dose and patients had breakfast. After 2 hours post – prandial blood 
sugar was measured by calorimetric method. 
The results were tabulated 
Details of hyperglycemic symptoms were noted in the last 10 patients since a 
patient started on oral steroid minipulse had developed hyperglycemic 
symptoms(dryness of mouth). 
The presence or absence of the following hyperglycemic symptoms were noted: 
Increased frequency of urination 
Excessive thrist 
Dehydration – Dry mouth 
Nausea, vomiting 
Fatigue 
Confusion 
Lack of Concentration. 
STATISTICAL ANALYSIS 
Data were analyzed by paired “t” test. 
Data were expressed as mean. 
The chosen level of significance was p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results & Analysis 
RESULTS 
A total of twenty two patients were studied. The age of the patients ranged  
between 12 years and 56 years with a mean age of 31.18 years. Of the twenty two 
patients eight were men and fourteen were women. Out of the twenty two patients 
nine patients were diagnosed with Vitiligo, ten patients with alopecia areata, one 
patient with Lichen planus and two patients with chronic severe pruritus. 
The mean value of the fasting blood sugar (83.51) and post- parandial blood 
sugar before and after giving oral methyl prednisolone (112.77 and 112.40 
respectively) is shown in Table 1.The statistical analysis is shown in Table 2. 
The details of hyperglycemic symptoms which were noted in the ten patients 
is shown in Table 3. The mean value of post prandial blood sugar before and after 
giving steroid was 112.77 mg/dl and 142.41 respectively. The difference was 
statistically significant (P value was 0.000782). 
The standard deviation of the fasting blood sugar, post prandial blood sugar 
levels (7.04, 21.66 and 31.23 respectively) showed that there is a wide range of post -
prandial blood sugar levels after giving oral methyl predinisolone. Out of ten patients 
who were enquired about hyperglycemic symptoms two patients had excessive thirst 
and two had symptoms of dehydration like dry mouth. 
Table – 1 
Mean Value of Fasting & Post prandial blood sugar before & after 
giving steroid 
Fasting Blood Sugar Before Steroid After Steroid 
83.54545 112.7727 142.4091 
Table - 2  
Statistical Analysis  
 
 Mean S.D T Value P Value 
FBS 
& 
PPBS Presteroid 
83.54545 
112.7727 
7.042235 
21.6615 
6.1449 0.000004263 
FBS 
& 
PPBS Post steroid 
83.54545 
142.4091 
7.042235 
31.23743 
8.2709 0.00000004808
PPBS Presteroid 
& 
PPBS Post steroid 
112.7727 
142.4091 
21.6615 
31.23743 
7.9595 0.00000008933
 
Table - 3  
Details of Hyperglycemic Symptoms 
Hyperglycemic Symptoms No of Patients. 
Increased frequency of urination - 
Excessive thirst 2 
Dehydration – dry mouth 2 
Nausea 0 
Vomiting 0 
Other Symptoms 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
DISCUSSION 
Steriods are commonly used in autoimmune disease like pemphigus57, Bullous 
pemphigoid, Alopecia areata, Vitiligo and other dermatological diseases. Pulse 
therapy with supra pharmacological doses of steroids is effective and it is associated 
with fewer side effects than conventional doses of steriods 57, the exact mechanism of 
pulse therapy is not known and postulated to be due to sequestration of 
lymphocytes58. Intravenous Dexamethasone in the form of Dexa methasone 
cyclophosphamide pulse therapy has been proved success in the treatment of various 
disorders like pemphigus57. Its chief aim is to provide maximum efficacy with 
minimal side effects.With similar intention, oral minipulse in the form of 
betamethasone or methylpredinisolone has been used in alopecia areta, vitiligo 
patients 3, 4, 5.  
Oral minipulse may be used for a longer periods with minimal side effects 
when compared to daily doses of corticosteroids. Systemic corticosteroids has been 
associated with side effects like hypertension, hyperglycemia, eye changes like 
cataract and glaucoma, electrolyte imbalance and bone changes like osteoporosis and 
vascular necrosis. 
Corticosteroids stimulate glycogenolysis and gluconeogenesis and increased 
peripheral insulin. resistance theraby leads to hyperglycemia 59. The pattern of steroid 
induced hyperglycemia is post prandial hyperglycemia 59, but does not effecting 
fasting blood sugar levels. 
In our study there was a significant rise in post prandial blood sugar after 
giving oral methylprednisolone pulse. The standard deviation of fasting blood sugar, 
post prandial blood sugar before and after steroids (7.04, 21.66 and 31.23 respectively 
) showed that there is a wide range of post prandial blood sugar values after giving 
oral steroids. 
In one study conducted in 25 patients with neurological disease treated with 
prednisolone 30 mg/daily, thirteen patients developed steroid induced diabetic 
mellitus following steroid therapy for more than 2 weeks. 59 
In another study involving patients with rheumatoid arthritis on corticosteroids 
therapy 8 % of the non – diabetic patients developed diabetes mellitus and 6 patients 
with Diabetes in whom glycemic control worsened.42 
In yet another study which was a retrospective review of pateients hospitalized 
for various conditions over one month period in those receiving steroids, 
hyperglycemia was documented in 32 of 50 patients and multiple hyperglycemia 
episodes occurred in 26 (52%). Among patients without a history of diabetes 19 of 34 
(56%) had hyperglycemia at least once.6 
Life threatening complication like steroids induced diabetic ketoacidosis has 
been reported56. We initiated this study since one of our patient who was on 
methylprednisolone pulse therapy for vitiligo met with an accident following which 
his blood sugar increased more than 450mg/dl and emergency measures were required 
to reduce the blood sugar levels.Hyperglycemic symptoms were observed in four out 
of ten patients (40%). Out of those four patients PPBS was more than 190 mg/dl in 
two patients and the other two patients had PPBS more than 140 mg/ dl. This showed 
that the hyperglycemic symptoms were common in patients with high Blood sugar 
levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
CONCLUSION 
We suggest that all the patients treated with either steroid pulse or oral 
minipulse should undergo fasting blood sugar and post prandial blood sugar before 
and after steroids. 
And the physician should be alert regarding the symptoms associated with 
hyperglycemia. 
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Annexures  
MASTER CHART 
S. No Name Sex Age FBS PPBS PPBS 
1 Arul Kumar M 26 95 101 132 
2 Elakkiya F 18 98 115 136 
3 Sathya F 21 84 92 117 
4 Saraswathy F 24 77 122 167 
5 Thayammal F 51 97 107 131 
6 Kalimuthu M 56 84 166 174 
7 Malathi F 26 81 96 116 
8 Bhagavathy F 33 74 132 198 
9 Dhanabhagyam F 38 89 152 178 
10 Eswari F 24 83 99 136 
11 Gunesekaran M 31 78 120 168 
12 Gopalasundaram M 35 83 125 165 
13 Kalai Selvi F 17 86 113 121 
14 Pappathy F 49 95 126 144 
15 Sangeetha F 12 82 97 100 
16 Veeraiyan M 53 80 88 96 
17 Priyadharshini F 21 77 138 201 
18 Kumar M 27 82 94 121 
19 Selvi F 25 80 88 104 
20 Thilaga F 32 79 126 174 
21 Palanisamy M 43 78 86 112 
22 Mani M 48 76 98 142 
 Total 83.54545 112.7727 142.4091 
 
